Saint Luke’s Koontz Center for Advanced Breast Cancer Announces New Clinical Trial for Metastatic Triple Negative Breast Cancer

September 28, 2017

Metastatic triple negative breast cancer remains the most challenging subtype of breast cancer to treat. The Saint Luke’s Koontz Center for Advanced Breast Cancer will be one of five sites in the United States participating in novel clinical trial designed to test the effectiveness of a new combination of cancer drugs designed to treat triple negative breast cancer (TNBC).

Find out what this means for metastatic breast cancer patients by reading the full story here.

Related Content

Saint Luke’s Koontz Center for Advanced Breast Cancer Announces New Clinical Trial for Metastatic Triple Negative Breast Cancer
The clinic will be one of five sites in the United States participating in novel clinical trial designed to test the effectiveness of a new combination of cancer drugs designed to treat triple negative breast cancer (TNBC).
KC Star: Woman Finds New Hope at Saint Luke's Koontz Center
The Koontz Center for Advanced Breast Cancer has a singular goal: improving the outcomes and quality of life for women with advanced (metastatic) breast cancer.